Di Peng

TL;DR: A molecular link between epithelial-to-mesenchymal transition (EMT) and CD8+ TIL immunosuppression and cancer progression is demonstrated and ZEB1 promotes metastasis through a heretofore unappreciated cell non-autonomous mechanism, and subgroups of patients in whom malignant progression is driven by EMT activators may respond to treatment with PD-L1 antagonists.

TL;DR: It is observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment, providing a novel mechanism of acquired resistance to immune checkpoint therapy.

TL;DR: It is found that FBXO17 specifically interacts with IFN regulatory factor 3 (IRF3) and decreases its dimerization and nuclear translocation and a novel mechanism for IRF3 deactivation by F-box protein-mediated recruitment of PP2A is demonstrated.

TL;DR: It is shown in a KrasLA1/+p53R172HΔg/+-based mouse model that bone morphogenetic protein-4 augments the expression of the T cell co-inhibitory receptor ligand PD-L1 in the mesenchymal subset of lung cancer cells, leading to profound CD8+ T cell-mediated immunosuppression, producing tumor growth and metastasis.

TL;DR: In this paper , the authors showed that the m6A reader Ythdc1 is indispensable for mouse skeletal muscle regeneration and proliferation of muscle stem cells, and they showed that in the absence of this reader, muscle cells in adult mice are unable to exit from quiescence.